

THE DISTILLERY

This week in therapeutics

	Target/marker/			Publication and contact
Indication	pathway	Summary	Licensing status	information
Autoimmune disea	ise			
Inflammatory bowel disease (IBD)	IL-6	A study in mice suggests that antagonizing IL-6 could help treat IBD. In a mouse model of CD8 ⁺ T cell-dependent severe autoimmune colitis, an anti-IL-6 receptor antibody lowered weight loss (p <0.05) and thickening of the large intestine compared with what was seen in untreated controls. Further studies are necessary to determine the role of IL-6 in human colitis and other immune-mediated diseases. No fewer than four companies have compounds targeting IL-6 to treat autoimmune disease in development ranging from clinical to registration.	Patent application filed in the U.S. for the colitis model; available for licensing	Tajima, M. <i>et al. J. Exp. Med.</i> ; published online April 22, 2008; doi:10.1084/jem.20071133 Contact: Takashi Nishimura, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japa e-mail: tak24@igm.hokudai.ac.jp